AUS
NZ
UK
CA
USA
IND
Highlights:
Ethics approval secured for a Phase I trial of RC220 bisantrene targeting solid tumors.
Patient enrollment set to begin at Southside Cancer Care Centre, with trial expansion planned.
Study to assess safety, tolerability, and pharmacokinetics in a dose-escalation format.
Race Oncology (ASX:RAC), a company specializing in cancer therapeutics, has received ethics approval from the Bellberry Human Research Ethics Committee to initiate a Phase I clinical trial for RC220 bisantrene. This development represents a step forward in the pursuit of innovative treatments with a focus on reducing cardiotoxic effects while maintaining efficacy in treating solid tumors.
Clinical Trial Implementation
The trial's first stage will commence at the Southside Cancer Care Centre in Miranda, pending final institutional approvals. Conducted in collaboration with the Cancer Care Foundation, the study will expand across additional locations, including sites in Hong Kong and South Korea, as regulatory approvals are completed. This expansion aims to facilitate broader patient participation and data collection.
Trial Structure and Study Focus
The study is designed to assess the safety, tolerability, and pharmacokinetics of RC220 bisantrene. The first stage involves dose escalation in participants to establish optimal dosing parameters. Following this, the second stage will focus on individuals who have not previously undergone anthracycline treatment. This approach will allow for a closer evaluation of both safety and cardioprotective aspects alongside the treatment's anticancer effects.
Enhanced Drug Formulation
RC220 represents a reformulation of bisantrene, an anthracene derivative that has previously demonstrated effectiveness against certain cancers. The updated version is engineered for improved usability and reduced cardiotoxicity. Given its modified formulation, regulatory guidelines necessitate a first-in-human trial designation, requiring a structured dose-escalation process to establish safety and efficacy parameters.
Broader Implications for Cancer Care
The initiation of this clinical trial underscores an ongoing commitment to exploring treatment options that minimize adverse effects while maintaining therapeutic efficacy. As the study progresses, further insights will emerge regarding the potential applications of RC220 in clinical oncology settings.
